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Psychiatric comorbidity is extremely common in bipolar
disorder (BD). More than half of BD patients have an additional
diagnosis, one of the most difﬁcult to manage being obsessive–
compulsive disorder (OCD) (Amerio et al., 2014). In our recent
meta-analysis, the pooled prevalence of OCD in BD was 17.0% (95%
CI 12.7–22.4%), which was comparable to the results reported by
the pooled prevalence of BD in OCD (18.35%, 95% CI 13.2–24.8%)
(Amerio et al., 2015).
The meaning of this comorbidity has not been clariﬁed yet
(Tonna et al., 2015). Although recent studies have investigated the
co-occurrence of anxiety and bipolar disorders, the topic is
insufﬁciently studied and Axis I/Axis II comorbidities in BD-OCD
patients remain unclear. We updated our recent systematic review
to speciﬁcally investigate psychiatric comorbidities in BD-OCD
patients.
Studies published in English through 30 November 2015 were
identiﬁed by searching the electronic databases MEDLINE, Embase,
and PsycINFO. We combined the search strategy of free text terms
and exploded MESH headings for the topics of bipolar disorder,
obsessive–compulsive disorder, and treatment combined asTable 1
Studies that met inclusion/exclusion criteria for systematic review.
References Study design Country Study population 
Issler et al. (2010)1 Case control study Brazil BD (n = 30, mean age:
BD = 41.8  10.5,
OCD-BD = 38.9  10.7)
Maina et al. (2007)2 Case control
study
Italy OCD (n = 204, mean
age = 34.7  12.1)
Masi et al. (2004)3 Case control study Italy BD, OCD, BD-OCD
(n = 102, mean
age = 14.2  3.2)
Masi et al. (2007)4 Prospective cohort
study
Italy OCD (n = 120, mean
age = 13.7  2.8)
Perugi et al. (2002)5 Case control study Italy OCD-MDE (n = 68, mean
age = 34.2  12.5); BD-
OCD (n = 38, mean
age = 35.9  12.2)
Shashidhara et al.
(2015)6
Cross-sectional study India BD-I (n = 396, age > 18) 
http://dx.doi.org/10.1016/j.ajp.2016.02.009
1876-2018/ 2016 Elsevier B.V. All rights reserved.following: (((((((((‘‘Bipolar Disorder’’[Mesh]) OR Bipolar disorder)
OR BD) OR Bipolar) OR Manic depressive disorder) OR Manic
depressive) OR Manic)) AND ((((‘‘Obsessive–Compulsive Disor-
der’’[Mesh]) OR OCD) OR Obsessive–compulsive) OR Obsessive–
compulsive disorder))).
Seven studies were selected (Table 1). Conﬁrming previous
studies, one report showed that BD-OCD patients were over two
times as likely to be also diagnosed with panic disorder,
agoraphobia, post-traumatic stress disorder and eating disorder
versus patients without comorbidity. When assessed in child and
adolescent populations, higher rates of attention-deﬁcit/hyper-
activity disorder, oppositional-deﬁant disorder and lower rates of
generalized anxiety disorder were reported in BD-OCD patients as
compared to non-comorbid patients.
Only two studies assessed Axis II comorbidities comparing BD-
OCD and non-BD-OCD patients. On the one hand, one case control
study conducted in Italy reported higher rates of at least one
Cluster A Personality Disorder, at least one Cluster B Personality
Disorder, and Narcissistic and Antisocial Personality Disorder in
subjects with comorbidity. On the other hand, a recent cross-
sectional study conducted in India reported higher prevalence
rates of anxious avoidant personality disorder in BD-OCD patients
compared to non-comorbid patients.Diagnosis
assessment
Results Quality*
SCID-P; DSM-IV Higher prevalence rates of any anxiety disorder
other than OCD (93.3% vs. 53.3%), impulse control
disorders (60% vs. 13.3%), ED (33.3% vs. 0%) and tic
disorder (33.3% vs. 0%) in OCD-BD vs. non-OCD-BD
17/31
SCID; DSM-IV Higher rates of ADHD-CD (51.3% vs. 20.0%) and CD
(29.7% vs. 13.3%) in BD vs. BD-OCD. Lower rates of
ADHD (2.8% vs. 16.7%) and higher rates of GAD
(77.1% vs. 16.7%) in OCD vs. BD-OCD
21/31
DICA-R; DSM-IV Higher rates of at least one cluster A personality
disorder, at least one cluster B personality disorder,
and narcissistic and antisocial personality disorder
in BD-OCD vs. non-BD-OCD
21/31
K-SADS-PL or
DICA-R; DSM-IV
Higher comorbidity with ADHD and ODD, and a
lower comorbidity with GAD in BD-OCD
21/31
SCID; DSM-IV Higher rates of current comorbidity with panic
disorder-agoraphobia in BD-OCD vs. non-BD-OCD
(52.6% vs. 16.7%).
20/31
SCID; DSM-IV Statistically non-signiﬁcant trends of higher
prevalence of agoraphobia and social phobia in
BD-OCD vs. non-BD-OCD; higher prevalence rates
of anxious avoidant personality disorder in BD-OCD
vs. non-BD-OCD
23/31
Table1 (Continued )
References Study design Country Study population Diagnosis
assessment
Results Quality*
Timpano et al. (2012)7 Case control study USA OCD (n = 605, mean
age = 39.2)
SCID-P; DSM-IV BD-OCD pt. were over two times as likely to be also
diagnosed with PD (OR 2.26, 95%CI = 1.38–3.71),
agoraphobia (OR 2.30, 95%CI = 1.35–3.91), PTSD
(OR 2.85, 95%CI = 1.49–5.45) and ED (OR 2.03,
95%CI = 1.14–3.60) vs. pt. without comorbidity
20/31
BD: bipolar disorder; OCD: obsessive–compulsive disorder; MDE: major depressive episode; GAD: generalized anxiety disorder; PD: panic disorder; PTSD: post-traumatic
stress disorder; ED: eating disorder; ADHD: attention deﬁcit hyperactivity disorder; CD: conduct disorder; ODD: oppositional-deﬁant disorder; DSM: Diagnostic and
Statistical Manual of Mental Disorders; SCID: Structured Clinical Interview; SCID-P: Structured Clinical Interview Patient Version; K-SADS-PL: Schedule for Affective
Disorders and Schizophrenia for School Age Children-Present and Lifetime Version; DICA-R: Diagnostic Interview for Children and Adolescents-Revised; vs.: versus.
* Checklist for measuring study quality developed by Downs and Black; (a) Episodic OCD: at least one circumscribed symptom-free interval (six months) was present; (b)
Chronic OCD: if symptoms persisted for most of the course, causing signiﬁcant distress and impairment in functioning; (c) Chronic BD: if all criteria for a major mood episode
were met continuously for at least two years. Differences statistically signiﬁcant (p < 0.05).
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Letter to Editor / Asian Journal of Psychiatry 21 (2016) 23–2424Results from this systematic review conﬁrm that psychiatric
comorbidities in BD-OCD patients are a common condition and
they deserve attention because of their clinical and therapeutic
implications.
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